Evidence map›Paper›PMID 36678643›Full record

ReviewPharmaceutics2022

Revolutionizing Therapeutic Delivery with Microneedle Technology for Tumor Treatment.

Vaibhavi Meghraj Desai, Sakshi Priya, Srividya Gorantla, Gautam Singhvi

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vaibhavi Meghraj DesaiIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Pilani Campus, Pilani 333031, India.
Sakshi PriyaIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Pilani Campus, Pilani 333031, India.
Srividya GorantlaIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Pilani Campus, Pilani 333031, India.
Gautam SinghviIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Pilani Campus, Pilani 333031, India.ORCID 0000-0002-9706-9244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor is an uncontrolled growth of tissue that can be localized (benign) or possesses the capability of metastasis (malignant). The conventional methods of tumor diagnosis, such as acupuncture, endoscopy, and histopathology, and treatment methods, such as injections, chemotherapy, surgery, and radiotherapy, are invasive, expensive, and pose severe safety and management issues for the patients. Microneedle technology is a recently developed approach for active transdermal drug delivery. It is minimally invasive, self-administrable, bypasses the first-pass effect, and effectively delivers chemotherapeutics and drugs at low doses, thus, overcoming the drawbacks of conventional delivery systems. This review provides an idea of the types, materials utilized in the fabrication, and techniques used for the preparation of microneedles (MNs), as well as their application in tumor diagnosis and treatment. Additionally, emphasis is given to the case studies related to MNs-assisted tumor therapy, such as photothermal therapy, gene therapy, photodynamic therapy, chemotherapy, immunotherapy, and various combination therapies. MNs also serve as a tool for diagnosis by the bio-sampling of blood and interstitial skin fluid, as well as biosensing various cancer biomarkers. The combined therapy and diagnostics provide theranostic MNs for enhanced and personalized tumor therapy. The limitations and prospects of MNs development are also discussed.

Indexed as

chemotherapymicroneedlestheranostictumor diagnosistumor therapy

Identifiers

PMID36678643
PMCPMC9866211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.